Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Entropy Neurodynamics Limited

ENP.AXASX
Healthcare
Biotechnology
$0.03
$-0.00(-3.03%)
Australian Market opens in 5h 53m

Entropy Neurodynamics Limited Fundamental Analysis

Entropy Neurodynamics Limited (ENP.AX) shows weak financial fundamentals with a PE ratio of -9.17, profit margin of 0.00%, and ROE of -1.05%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.17
Current Ratio9.08

Areas of Concern

ROE-1.05%
Operating Margin0.00%
We analyze ENP.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -93.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-93.2/100

We analyze ENP.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

ENP.AX struggles to generate sufficient returns from assets.

ROA > 10%
-80.03%

Valuation Score

Excellent

ENP.AX trades at attractive valuation levels.

PE < 25
-9.17
PEG Ratio < 2
-0.17

Growth Score

Weak

ENP.AX faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

ENP.AX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
9.08

Profitability Score

Weak

ENP.AX struggles to sustain strong margins.

ROE > 15%
-104.56%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is ENP.AX Expensive or Cheap?

P/E Ratio

ENP.AX trades at -9.17 times earnings. This suggests potential undervaluation.

-9.17

PEG Ratio

When adjusting for growth, ENP.AX's PEG of -0.17 indicates potential undervaluation.

-0.17

Price to Book

The market values Entropy Neurodynamics Limited at 8.20 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

8.20

EV/EBITDA

Enterprise value stands at -8.46 times EBITDA. This is generally considered low.

-8.46

How Well Does ENP.AX Make Money?

Net Profit Margin

For every $100 in sales, Entropy Neurodynamics Limited keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-1.05 in profit for every $100 of shareholder equity.

-1.05%

ROA

Entropy Neurodynamics Limited generates $-80.03 in profit for every $100 in assets, demonstrating efficient asset deployment.

-80.03%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.01 in free cash annually.

$-0.01

FCF Yield

ENP.AX converts -14.37% of its market value into free cash.

-14.37%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-9.17

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.17

vs 25 benchmark

P/B Ratio

Price to book value ratio

8.20

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

9.08

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.05

vs 25 benchmark

ROA

Return on assets percentage

-0.80

vs 25 benchmark

ROCE

Return on capital employed

-1.13

vs 25 benchmark

How ENP.AX Stacks Against Its Sector Peers

MetricENP.AX ValueSector AveragePerformance
P/E Ratio-9.1728.25 Better (Cheaper)
ROE-104.56%780.00% Weak
Net Margin0.00%-20122.00% (disorted) Weak
Debt/Equity0.000.30 Strong (Low Leverage)
Current Ratio9.084.66 Strong Liquidity
ROA-80.03%-14687.00% (disorted) Weak

ENP.AX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Entropy Neurodynamics Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ